{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:27:31Z","timestamp":1778887651048,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malaria remains a public health concern globally. Resistance to anti-malarial drugs has consistently threatened the gains in controlling the malaria parasites. Currently, artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) are the treatment regimens against <jats:italic>Plasmodium falciparum<\/jats:italic> infections in many African countries, including Kenya. Recurrent infections have been reported in patients treated with AL or DP, suggesting the possibility of reinfection or parasite recrudescence associated with the development of resistance against the two therapies. The <jats:italic>Plasmodium falciparum<\/jats:italic> cysteine desulfurase IscS (<jats:italic>Pfnfs1<\/jats:italic>) K65 selection marker has previously been associated with decreased lumefantrine susceptibility. This study evaluated the frequency of the <jats:italic>Pfnfs1<\/jats:italic> K65 resistance marker and associated K65Q resistant allele in recurrent infections collected from <jats:italic>P. falciparum<\/jats:italic>-infected individuals living in Matayos, Busia County, in western Kenya.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Archived dried blood spots (DBS) of patients with recurrent malaria infection on clinical follow-up days after treatment with either AL or DP were used in the study. After extraction of genomic DNA, PCR amplification and sequencing analysis were employed to determine the frequencies of the <jats:italic>Pfnfs1<\/jats:italic> K65 resistance marker and K65Q mutant allele in the recurrent infections. <jats:italic>Plasmodium falciparum msp1<\/jats:italic> and <jats:italic>P. falciparum msp2<\/jats:italic> genetic markers were used to distinguish recrudescent infections from new infections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The K65 wild-type allele was detected at a frequency of 41% while the K65Q mutant allele was detected at a frequency of 22% in the recurrent samples. 58% of the samples containing the K65 wild-type allele were AL treated samples and while 42% were DP treated samples. 79% of the samples with the K65Q mutation were AL treated samples and 21% were DP treated samples. The K65 wild-type allele was detected in three recrudescent infections (100%) identified from the AL treated samples. The K65 wild-type allele was detected in two recrudescent DP treated samples (67%) while the K65Q mutant allele was identified in one DP treated (33%) recrudescent sample.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The data demonstrate a higher frequency of the K65 resistance marker in patients with recurrent infection during the study period. The study underscores the need for consistent monitoring of molecular markers of resistance in regions of high malaria transmission.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-023-04587-2","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T02:02:17Z","timestamp":1684461737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya"],"prefix":"10.1186","volume":"22","author":[{"given":"Beatrice","family":"Gachie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin","family":"Thiong\u2019o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Muriithi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Chepngetich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Onchieku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremiah","family":"Gathirwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mwitari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Magoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kiboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Kimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"4587_CR1","volume-title":"Word Malaria Report 2021","author":"WHO","year":"2021","unstructured":"WHO. Word Malaria Report 2021. Geneva: World Health Organization; 2021."},{"issue":"Suppl 6","key":"4587_CR2","first-page":"181","volume":"77","author":"NJ White","year":"2007","unstructured":"White NJ, Nosten F. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77(Suppl 6):181\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"4587_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1473-3099(18)30068-9","volume":"18","author":"R Amato","year":"2018","unstructured":"Amato R, Pearson RD, Almagro-Garcia J, Amaratunga C, Lim P, Suon S, et al. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect Dis. 2018;18:337\u201345.","journal-title":"Lancet Infect Dis"},{"key":"4587_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264339","volume":"17","author":"K Marwa","year":"2022","unstructured":"Marwa K, Kapesa A, Baraka V, Konje E, Kidenya B, Mukonzo J, et al. Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2022;17: e0264339.","journal-title":"PLoS ONE"},{"key":"4587_CR5","doi-asserted-by":"publisher","first-page":"8907","DOI":"10.1038\/s41598-020-65553-5","volume":"10","author":"MA Diallo","year":"2020","unstructured":"Diallo MA, Yade MS, Ndiaye YD, Diallo I, Diongue K, Sy SA, et al. Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal. Sci Rep. 2020;10:8907.","journal-title":"Sci Rep"},{"key":"4587_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12936-019-2864-1","volume":"18","author":"M Warsame","year":"2019","unstructured":"Warsame M, Hassan AM, Hassan AH, Jibril AM, Khim N, Arale AM, et al. High therapeutic efficacy of artemether\u2013lumefantrine and dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated falciparum malaria in Somalia. Malar J. 2019;18:231.","journal-title":"Malar J"},{"key":"4587_CR7","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"4587_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"4587_CR9","first-page":"1287","volume":"2","author":"DA Fidock","year":"2021","unstructured":"Fidock DA, Rosenthal PJ. Artemisinin resistance in Africa: how urgent is the threat? Med (NY). 2021;2:1287\u20138.","journal-title":"Med (NY)"},{"key":"4587_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12936-015-1075-7","volume":"15","author":"HC Slater","year":"2016","unstructured":"Slater HC, Griffin JT, Ghani AC, Okell LC. Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malar J. 2016;15:10.","journal-title":"Malar J"},{"key":"4587_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"4587_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12936-019-2701-6","volume":"18","author":"M Ocan","year":"2019","unstructured":"Ocan M, Akena D, Nsobya S, Kamya MR, Senono R, Kinengyere AA, et al. K13-propeller gene polymorphisms in Plasmodium falciparum parasite population in malaria affected countries: a systematic review of prevalence and risk factors. Malar J. 2019;18:60.","journal-title":"Malar J"},{"key":"4587_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.chom.2019.06.001","volume":"26","author":"LS Ross","year":"2019","unstructured":"Ross LS, Fidock DA. Elucidating mechanisms of drug-resistant Plasmodium falciparum. Cell Host Microbe. 2019;26:35\u201347.","journal-title":"Cell Host Microbe"},{"key":"4587_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","volume":"17","author":"R Amato","year":"2017","unstructured":"Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect Dis. 2017;17:164\u201373.","journal-title":"Lancet Infect Dis"},{"key":"4587_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-micro-020518-115546","volume":"74","author":"KJ Wicht","year":"2020","unstructured":"Wicht KJ, Mok S, Fidock DA. Molecular mechanisms of drug resistance in Plasmodium falciparum malaria. Annu Rev Microbiol. 2020;74:431\u201354.","journal-title":"Annu Rev Microbiol"},{"key":"4587_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1086\/507115","volume":"194","author":"ABS Sidhu","year":"2006","unstructured":"Sidhu ABS, Uhlemann A-C, Valderramos SG, Valderramos J-C, Krishna S, Fidock DA. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis. 2006;194:528\u201335.","journal-title":"J Infect Dis"},{"key":"4587_CR17","volume-title":"Report on antimalarial drug efficacy, resistance and response","author":"WHO","year":"2019","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response. Geneva: World Health Organization; 2019."},{"key":"4587_CR18","unstructured":"Division of National Malaria Programme (DNMP) [Kenya], ICF. Kenya Malaria Indicator Survey 2020. Nairobi, Kenya and Rockville, USA. 2021;158"},{"key":"4587_CR19","unstructured":"Kenya National Bureau of Statistics. Economic survey 2018. Nairobi, Kenya 2018."},{"key":"4587_CR20","unstructured":"Kenya MOH. National malaria treatment guidelines. Nairobi, Kenya 2006;"},{"key":"4587_CR21","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820003167","volume":"149","author":"G Kishoyian","year":"2021","unstructured":"Kishoyian G, Njagi ENM, Orinda GO, Kimani FT, Thiongo K, Matoke-Muhia D. Efficacy of artemisinin-lumefantrine for treatment of uncomplicated malaria after more than a decade of its use in Kenya. Epidemiol Infect. 2021;149: e27.","journal-title":"Epidemiol Infect"},{"key":"4587_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12936-020-03358-7","volume":"19","author":"W Chebore","year":"2020","unstructured":"Chebore W, Zhou Z, Westercamp N, Otieno K, Shi YP, Sergent SB, et al. Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya. Malar J. 2020;19:291.","journal-title":"Malar J"},{"key":"4587_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.12688\/wellcomeopenres.17656.1","volume":"7","author":"I Omedo","year":"2022","unstructured":"Omedo I, Bartilol B, Kimani D, Goncalves S, Drury E, Rono MK, et al. Spatio-temporal distribution of antimalarial drug resistant gene mutations in a Plasmodium falciparum parasite population from Kilifi, Kenya: a 25-year retrospective study [version 1; peer review: 2 approved with reservations]. Wellcome Open Res. 2022;7:45.","journal-title":"Wellcome Open Res"},{"key":"4587_CR24","doi-asserted-by":"publisher","first-page":"9687","DOI":"10.1038\/s41598-018-28017-5","volume":"8","author":"A Amambua-Ngwa","year":"2018","unstructured":"Amambua-Ngwa A, Jeffries D, Amato R, Worwui A, Karim M, Ceesay S, et al. Consistent signatures of selection from genomic analysis of pairs of temporal and spatial Plasmodium falciparum populations from The Gambia. Sci Rep. 2018;8:9687.","journal-title":"Sci Rep"},{"key":"4587_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exppara.2019.01.015","volume":"198","author":"ZR Pala","year":"2019","unstructured":"Pala ZR, Saxena V, Saggu GS, Mani SK, Pareek RP, Kochar SK, et al. Functional analysis of iron-sulfur cluster biogenesis (SUF pathway) from Plasmodium vivax clinical isolates. Exp Parasitol. 2019;198:53\u201362.","journal-title":"Exp Parasitol"},{"key":"4587_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003655","volume":"9","author":"JE Gisselberg","year":"2013","unstructured":"Gisselberg JE, Dellibovi-Ragheb TA, Matthews KA, Bosch G, Prigge ST. The suf iron-sulfur cluster synthesis pathway is required for apicoplast maintenance in malaria parasites. PLoS Pathog. 2013;9: e1003655.","journal-title":"PLoS Pathog"},{"key":"4587_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1039\/C7MT00180K","volume":"10","author":"C Wachnowsky","year":"2018","unstructured":"Wachnowsky C, Fidai I, Cowan JA. Iron-sulfur cluster biosynthesis and trafficking\u2014impact on human disease conditions. Metallomics. 2018;10:9\u201329.","journal-title":"Metallomics"},{"key":"4587_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003227","volume":"9","author":"TA Dellibovi-Ragheb","year":"2013","unstructured":"Dellibovi-Ragheb TA, Gisselberg JE, Prigge ST. Parasites FeS Up: iron-sulfur cluster biogenesis in eukaryotic pathogens. PLoS Pathog. 2013;9: e1003227.","journal-title":"PLoS Pathog"},{"key":"4587_CR29","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/mmi.14735","volume":"116","author":"M Sadik","year":"2021","unstructured":"Sadik M, Afsar M, Ramachandran R, Habib S. [Fe-S] biogenesis and unusual assembly of the ISC scaffold complex in the Plasmodium falciparum mitochondrion. Mol Microbiol. 2021;116:606\u201323.","journal-title":"Mol Microbiol"},{"key":"4587_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12936-019-2876-x","volume":"18","author":"IM Bashir","year":"2019","unstructured":"Bashir IM, Nyakoe N, Van Der Sande M. Targeting remaining pockets of malaria transmission in Kenya to hasten progress towards national elimination goals: an assessment of prevalence and risk factors in children from the Lake endemic region. Malar J. 2019;18:233.","journal-title":"Malar J"},{"key":"4587_CR31","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0169-4758(98)01340-4","volume":"14","author":"G Snounou","year":"1998","unstructured":"Snounou G, Beck HP. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today. 1998;14:462\u20137.","journal-title":"Parasitol Today"},{"key":"4587_CR32","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/molbev\/msy096","volume":"35","author":"S Kumar","year":"2018","unstructured":"Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35:1547\u20139.","journal-title":"Mol Biol Evol"},{"key":"4587_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12936-018-2509-9","volume":"17","author":"NJ White","year":"2018","unstructured":"White NJ. Anaemia and malaria. Malar J. 2018;17:371.","journal-title":"Malar J"},{"key":"4587_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0169-4758(00)01774-9","volume":"16","author":"C Menendez","year":"2000","unstructured":"Menendez C, Fleming AF, Alonso PL. Malaria-related anaemia. Parasitol Today. 2000;16:469\u201376.","journal-title":"Parasitol Today"},{"key":"4587_CR35","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1128\/AAC.01636-09","volume":"54","author":"B Witkowski","year":"2010","unstructured":"Witkowski B, Leli\u00e8vre J, Barrag\u00e1n MJL, Laurent V, Su X, Berry A, et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob Agents Chemother. 2010;54:1872\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"4587_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1017\/S0031182099006332","volume":"121","author":"MB Hoshen","year":"2000","unstructured":"Hoshen MB, Na-Bangchang K, Stein WD, Ginsburg H. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of \u201cdormancy\u201d, a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology. 2000;121:237\u201346.","journal-title":"Parasitology"},{"key":"4587_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pctr.0020020","volume":"2","author":"MR Kamya","year":"2007","unstructured":"Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007;2: e20.","journal-title":"PLoS Clin Trials"},{"key":"4587_CR38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1475-2875-11-207","volume":"11","author":"AM Shaukat","year":"2012","unstructured":"Shaukat AM, Gilliams EA, Kenefic LJ, Laurens MB, Dzinjalamala FK, Nyirenda OM, et al. Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment. Malar J. 2012;11:207.","journal-title":"Malar J"},{"key":"4587_CR39","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12936-021-04021-5","volume":"20","author":"C Ebong","year":"2021","unstructured":"Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J. 2021;20:484.","journal-title":"Malar J"},{"key":"4587_CR40","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.4269\/ajtmh.21-0214","volume":"105","author":"LF Moriarty","year":"2021","unstructured":"Moriarty LF, Nkoli PM, Likwela JL, Mulopo PM, Sompwe EM, Rika JM, et al. Therapeutic efficacy of artemisinin-based combination therapies in Democratic Republic of the Congo and investigation of molecular markers of antimalarial resistance. Am J Trop Med Hyg. 2021;105:1067\u201375.","journal-title":"Am J Trop Med Hyg"},{"key":"4587_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20:48.","journal-title":"Malar J"},{"key":"4587_CR42","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1128\/AAC.00903-07","volume":"52","author":"K Stepniewska","year":"2008","unstructured":"Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother. 2008;52:1589\u201396.","journal-title":"Antimicrob Agents Chemother"},{"key":"4587_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1517\/14656566.8.1.75","volume":"8","author":"G Kokwaro","year":"2007","unstructured":"Kokwaro G, Mwai L, Nzila A. Artemether\/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother. 2007;8:75\u201394.","journal-title":"Expert Opin Pharmacother"},{"key":"4587_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1475-2875-11-217","volume":"11","author":"NX Thanh","year":"2012","unstructured":"Thanh NX, Trung TN, Phong NC, Quang HH, Dai B, Shanks GD, et al. The efficacy and tolerability of artemisinin-piperaquine (Artequick\u00ae) versus artesunate-amodiaquine (Coarsucam\u2122) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. Malar J. 2012;11:217.","journal-title":"Malar J"},{"key":"4587_CR45","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1086\/596738","volume":"199","author":"C Sisowath","year":"2009","unstructured":"Sisowath C, Petersen I, Veiga MI, M\u00e5rtensson A, Premji Z, Bj\u00f6rkman A, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009;199:750\u20137.","journal-title":"J Infect Dis"},{"key":"4587_CR46","doi-asserted-by":"publisher","first-page":"e01067","DOI":"10.1128\/AAC.01067-19","volume":"63","author":"K Wamae","year":"2019","unstructured":"Wamae K, Okanda D, Ndwiga L, Osoti V, Kimenyi KM, Abdi AI, et al. No evidence of Plasmodium falciparum k13 artemisinin resistance-conferring mutations over a 24-year analysis in Coastal Kenya but a near complete reversion to chloroquine-sensitive parasites. Antimicrob Agents Chemother. 2019;63:e01067-e1119.","journal-title":"Antimicrob Agents Chemother"},{"key":"4587_CR47","doi-asserted-by":"publisher","first-page":"e01949","DOI":"10.1128\/AAC.01949-20","volume":"65","author":"PR Dimbu","year":"2021","unstructured":"Dimbu PR, Horth R, C\u00e2ndido ALM, Ferreira CM, Caquece F, Garcia LEA, et al. Continued low efficacy of artemether-lumefantrine in Angola in 2019. Antimicrob Agents Chemother. 2021;65:e01949-e2020.","journal-title":"Antimicrob Agents Chemother"},{"key":"4587_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taz082","author":"DL Bourque","year":"2020","unstructured":"Bourque DL, Chen LH. Plasmodium falciparum malaria recrudescence after treatment with artemether-lumefantrine. J Ttravel Med. 2020. https:\/\/doi.org\/10.1093\/jtm\/taz082.","journal-title":"J Ttravel Med"},{"key":"4587_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijid.2021.07.008","volume":"110","author":"A Silva-Pinto","year":"2021","unstructured":"Silva-Pinto A, Domingos J, Cardoso M, Reis A, Benavente ED, Caldas JP, et al. Artemether-lumefantrine treatment failure of uncomplicated Plasmodium falciparum malaria in travellers coming from Angola and Mozambique. Int J Infect Dis. 2021;110:151\u20134.","journal-title":"Int J Infect Dis"},{"key":"4587_CR50","first-page":"e02256","volume":"62","author":"KF Breglio","year":"2018","unstructured":"Breglio KF, Rahman RS, S\u00e1 JM, Hott A, Roberts DJ, Wellems TE. Kelch mutations in Plasmodium falciparum protein K13 do not modulate dormancy after artemisinin exposure and sorbitol selection in vitro. Antimicrob Agents Chemother. 2018;62:e02256-e2317.","journal-title":"Antimicrob Agents Chemother"},{"key":"4587_CR51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijpddr.2012.01.001","volume":"2","author":"Q Cheng","year":"2012","unstructured":"Cheng Q, Kyle DE, Gatton ML. Artemisinin resistance in Plasmodium falciparum: a process linked to dormancy? Int J Parasitol Drugs Drug Resist. 2012;2:249\u201355.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"4587_CR52","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1086\/656476","volume":"202","author":"F Teuscher","year":"2010","unstructured":"Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis. 2010;202:1362\u20138.","journal-title":"J Infect Dis"},{"key":"4587_CR53","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/infdis\/jiaa562","volume":"223","author":"C Peatey","year":"2021","unstructured":"Peatey C, Chen N, Gresty K, Anderson K, Pickering P, Watts R, et al. Dormant Plasmodium falciparum parasites in human infections following artesunate therapy. J Infect Dis. 2021;223:1631\u20138.","journal-title":"J Infect Dis"},{"key":"4587_CR54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1475-2875-10-297","volume":"10","author":"NJ White","year":"2011","unstructured":"White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297.","journal-title":"Malar J"},{"key":"4587_CR55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(07)60160-3","volume":"369","author":"A Ratcliff","year":"2007","unstructured":"Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007;369:757\u201365.","journal-title":"Lancet"},{"key":"4587_CR56","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1086\/432011","volume":"41","author":"EA Ashley","year":"2005","unstructured":"Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis. 2005;41:425\u201332.","journal-title":"Clin Infect Dis"},{"key":"4587_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011880","volume":"5","author":"N Valecha","year":"2010","unstructured":"Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS ONE. 2010;5: e11880.","journal-title":"PLoS ONE"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04587-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-023-04587-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04587-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:29:06Z","timestamp":1684466946000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-023-04587-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4587"],"URL":"https:\/\/doi.org\/10.1186\/s12936-023-04587-2","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Kenya Medical Research Institute\u2019s Scientific and Ethics Review Unit (KEMRI\/SERU).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}